- Home
- REAL vs ABUS Comparison
REAL vs ABUS Comparison
Compare REAL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ABUS
- Stock Information
- Founded
- REAL 2011
- ABUS 2005
- Country
- REAL United States
- ABUS United States
- Employees
- REAL N/A
- ABUS N/A
- Industry
- REAL Other Specialty Stores
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- REAL Consumer Discretionary
- ABUS Health Care
- Exchange
- REAL Nasdaq
- ABUS Nasdaq
- Market Cap
- REAL 641.9M
- ABUS 672.1M
- IPO Year
- REAL 2019
- ABUS N/A
- Fundamental
- Price
- REAL $5.65
- ABUS $3.36
- Analyst Decision
- REAL Buy
- ABUS Strong Buy
- Analyst Count
- REAL 5
- ABUS 4
- Target Price
- REAL $8.40
- ABUS $5.50
- AVG Volume (30 Days)
- REAL 4.5M
- ABUS 843.8K
- Earning Date
- REAL 05-08-2025
- ABUS 05-14-2025
- Dividend Yield
- REAL N/A
- ABUS N/A
- EPS Growth
- REAL N/A
- ABUS N/A
- EPS
- REAL N/A
- ABUS N/A
- Revenue
- REAL $616,717,000.00
- ABUS $6,403,000.00
- Revenue This Year
- REAL $11.45
- ABUS $14.57
- Revenue Next Year
- REAL $10.09
- ABUS $15.84
- P/E Ratio
- REAL N/A
- ABUS N/A
- Revenue Growth
- REAL 11.89
- ABUS N/A
- 52 Week Low
- REAL $2.24
- ABUS $2.71
- 52 Week High
- REAL $11.38
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- REAL 50.42
- ABUS 53.55
- Support Level
- REAL $4.98
- ABUS $3.04
- Resistance Level
- REAL $5.64
- ABUS $3.54
- Average True Range (ATR)
- REAL 0.33
- ABUS 0.14
- MACD
- REAL 0.00
- ABUS 0.02
- Stochastic Oscillator
- REAL 67.68
- ABUS 70.00
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.